Last updated: July 28, 2026
Executive summary: Biogen International GmbH sued Cipla Limited in 2019 in the District of Delaware over alleged patent infringement tied to Biogen’s neurology portfolio (case caption: Biogen International GmbH v. Cipla Limited, 1:19-cv-02210). The litigation’s commercial and regulatory relevance is tied to the risk of an infringement finding and any associated Hatch-Waxman/Orange Book enforcement around the asserted patents. This matter is high-stakes because it can accelerate or block generic entry depending on (1) which patents were asserted, (2) the claim scope Biogen proved in litigation, and (3) whether any final judgment, settlement, or consent judgment changed the launch timing and permissible product launch date.
No further case-specific litigation record can be produced here because the provided input contains only the docket number and party name. A complete and accurate litigation summary requires the asserted patent list, the specific filings (complaint, amended complaint, answers, Markman order, claim construction, dispositive motions), scheduled proceedings, and the case disposition (trial verdict, summary judgment, Rule 54 judgment, settlement terms, consent decree, or dismissal). Without those elements, any “hard data” would be speculative.
1:19-cv-02210 litigation overview: what is known from the docket metadata
- Case: Biogen International GmbH v. Cipla Limited
- Docket: 1:19-cv-02210
- Forum: District of Delaware (as reflected by the caption’s common association for Hatch-Waxman patent disputes)
The question of “what patents protect what product” and “when exclusivity expires” is not answerable from the docket number alone. The asserted patents, their expiration dates, and any PTO reexamination or terminal disclaimer terms drive the litigation posture and infringement analysis. Those facts must be sourced from the complaint and the court’s orders.
What patents were asserted in Biogen v. Cipla 1:19-cv-02210?
Featured snippet answer: Not determinable from the provided information. Patent-by-patent infringement analysis depends on the exact claims asserted and the asserted reference drug/ANDA product.
What data must be extracted to answer this accurately
- Complaint: asserted U.S. patent numbers and claim categories (composition, formulation, method of use, manufacture, etc.)
- Whether the case is framed as Hatch-Waxman (27/28 U.S.C. 1400(b), 21 U.S.C. § 355, and 35 U.S.C. § 271(e)(2) elements)
- Whether Cipla’s filing involved an ANDA paragraph IV, IV-to-approval timing, or other certification posture
What infringement theories did Biogen plead against Cipla in 1:19-cv-02210?
Featured snippet answer: Not determinable from the provided information. The infringement theories are claim-specific and depend on the accused product and the label/manufacturing process alleged in the complaint.
How courts typically evaluate these cases (what must be matched to the record)
- Direct infringement vs. infringement by process
- Doctrine of equivalents arguments
- Product-by-process limitations (if manufacturing steps are claimed)
- Treatment of design-around efforts (if Cipla’s ANDA carve-outs exist)
- Contributory or inducement theories (if pleaded)
Was there a Markman claim construction in 1:19-cv-02210, and how did it affect outcomes?
Featured snippet answer: Not determinable from the provided information. Markman rulings often drive summary judgment outcomes by narrowing claim scope.
What to look for in the docket
- Claim construction order date
- Rulings that narrow functional ranges, structural requirements, or priority terms
- Treatment of dependent claims relative to independent claim limitations
What motions decided key issues in Biogen v. Cipla 1:19-cv-02210?
Featured snippet answer: Not determinable from the provided information. Dispositive motions typically include:
- Motion to dismiss for pleading insufficiency (if raised)
- Summary judgment on infringement or invalidity
- Daubert rulings impacting expert testimony admissibility
Litigation mechanics that matter commercially
- Whether the court entered an injunction or stay tied to preliminary rulings
- Whether the case stayed pending IPRs or reexaminations
- Whether any final judgment triggered an FDA approval consequence
How did the court rule on infringement and validity in 1:19-cv-02210?
Featured snippet answer: Not determinable from the provided information. Outcomes can range from dismissal to summary judgment to trial verdict to settlement-driven dismissal.
What constitutes a business-relevant “win”
- Validity upheld vs. some claims invalidated
- Noninfringement findings that permit launch
- Final judgment defining the “safe launch” scope if products differ
- Judgment that affects only certain claim sets or only certain dosage forms
Did the parties settle, and did the settlement include launch or covenant terms?
Featured snippet answer: Not determinable from the provided information. Settlements in Hatch-Waxman often include:
- Expiry-triggered launch dates
- Carve-outs for non-infringing formulations
- Royalty or no-royalty arrangements
- Stipulations of dismissal with prejudice
Business impact: what to confirm in settlement terms
- Launch date (and whether it is tied to patent expiration, exclusivity, or entry triggers)
- Whether Cipla was permitted to launch “at risk”
- Whether any injunction entered and was dissolved
- Confidentiality provisions affecting enforcement
What is the Orange Book status of the relevant Biogen product tied to this litigation?
Featured snippet answer: Not determinable from the provided information. Orange Book status requires:
- The specific NDA/ANDA number
- The list of patents associated with the drug in question
- Expiration dates and whether listed patents match the asserted patents
What the Orange Book typically clarifies in patent disputes
- Patent-by-patent expiration dates (including pediatric exclusivity)
- Exclusivity end dates (5-year and 3-year exclusivity, if applicable)
- Whether asserted patents were Orange Book-listed at the time of ANDA submission
When does the relevant Biogen exclusivity expire, and how does that control generic timing?
Featured snippet answer: Not determinable from the provided information. Exclusivity timelines are NDA-specific and patent-specific.
Timing questions that cannot be answered without the asserted-patent list
- Do asserted patents expire before or after statutory exclusivity?
- Does the case involve method-of-use patents that may not block FDA approval but block therapeutic labeling?
- Is there pediatric extension or terminal disclaimer affecting enforceable dates?
What generic entry risks exist for Cipla’s ANDA in 1:19-cv-02210?
Featured snippet answer: Not determinable from the provided information. Entry risk is a function of:
- Whether the court entered an injunction or final noninfringement judgment
- Whether any remaining asserted claims survived dispositive motions
- Whether settlement permitted launch prior to certain dates
Risk analysis framework that must be matched to the docket outcome
- Remaining asserted patents post-dismissal or post-claim-construction
- Whether design-arounds altered claim coverage
- Whether FDA approval could precede patent resolution
How strong is Biogen’s patent estate in this dispute (patent count, expiration, breadth)?
Featured snippet answer: Not determinable from the provided information. “Strength” is not generic; it requires the specific asserted patent set, claim breadth, and their litigation/prosecution history.
What a strength assessment requires
- Priority dates and earliest filing
- Claim construction favorability
- Prior art landscape (obviousness challenges)
- Past litigation outcome patterns (other courts, other defendants)
Which other defendants or related cases overlap with 1:19-cv-02210?
Featured snippet answer: Not determinable from the provided information. Overlap matters for coordinated discovery, common claim construction, and settlement spillovers.
What to verify in related dockets
- Same asserted patents with different ANDA filers
- Coordinated claim construction orders
- Consolidation or parallel litigation schedules
Geographic scope: does the case affect only U.S. sales, or also foreign manufacturing?
Featured snippet answer: Not determinable from the provided information. In Hatch-Waxman, enforcement typically targets U.S. approval and U.S. infringement, while manufacturing and foreign export can be implicated depending on claim type and product flow.
Typical U.S.-centric consequences
- FDA approval decisions
- Importation and U.S. sale restrictions
- Injunction or consent order constraints
Commercial exposure: what revenues and market share are implicated by this litigation?
Featured snippet answer: Not determinable from the provided information. Market exposure requires:
- The specific Biogen drug (and dosage forms)
- The asserted market segment
- Prior annual prescription volumes or revenue estimates tied to the Orange Book-listed product
How does Biogen’s posture in 1:19-cv-02210 compare with other Biogen v. generic patent cases?
Featured snippet answer: Not determinable from the provided information. Comparable posture depends on:
- Similar claim types across cases
- Court tendencies in claim construction and invalidity rulings
- Settlement patterns
Key Takeaways
- This docket number and party caption alone do not provide the case-specific litigation record needed for a complete, accurate litigation summary with hard dates, rulings, and asserted patents.
- A business-ready analysis requires the asserted patent numbers, complaint allegations, procedural milestones, and the final case disposition (judgment or settlement), none of which are contained in the provided input.
FAQs
- What patents are commonly asserted by Biogen International GmbH in U.S. Hatch-Waxman cases involving generics?
- How do court claim construction rulings typically affect infringement outcomes in Delaware pharma patent cases?
- What docket entries signal settlement vs. trial in Hatch-Waxman patent litigation?
- How is “Orange Book listed” status used in proving infringement under 35 U.S.C. § 271(e)(2)?
- What factors influence whether an ANDA applicant can launch “at risk” after motions practice but before final judgment?
References (APA)
No sources were cited because no case filings, orders, or docket disposition details were provided.
